
Data supports imlifidase prior to gene therapy for Duchenne
Hansa Biopharma has announced topline results from three patients with Duchenne muscular dystrophy (DMD) treated with its imlifidase prior to receiving Sarepta’s Elevidys (delandistrogene moxeparvovec-rokl) in the SRP-9001-104 trial. After one dose of imlifidase, three patients experienced a rapid reduction of IgG antibodies, to levels ≥95% less… Read More











